SCHEMBL4038495

SCHEMBL4038495

O=C(O)C1=Cc2cnccc2Oc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
STK17B O94768 1/20 0.35
CDK8 P49336 2/20 0.34
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
APP P05067 1/20 0.33
GAA P10253 1/20 0.33
HCAR3 P49019 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
CYP19A1 P11511 1/20 0.32
KDM4C Q9H3R0 4/20 0.32
KDM4D Q6B0I6 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043208 0.83 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAOA
Hydrochloric Acid SCHEMBL4045240 0.82 LMNA (0.68) LMNAALDH1A1MEN1KMT2AMAOA
SCHEMBL24631747 0.81 LMNA (0.40) LMNAALDH1A1MEN1KMT2APKM
SCHEMBL24631371 0.77 ALDH1A1 (0.43) LMNASTK17BCDK8ALDH1A1KMT2A
SCHEMBL2827619 0.74 LMNA (0.59) LMNAALDH1A1MEN1KMT2ACYP2C9
SCHEMBL4037495 0.71 LMNA (0.56) LMNAALDH1A1MEN1KMT2AGPR84
SCHEMBL4038858 0.70 LMNA (0.54) LMNAALDH1A1MEN1KMT2AGPR84
SCHEMBL4213975 0.69 LMNA (0.52) LMNAALDH1A1MEN1KMT2AGPR84
SCHEMBL4043114 0.69 LMNA (0.46) LMNAALDH1A1MEN1KMT2ARAB9A
SCHEMBL4041075 0.69 LMNA (0.71) LMNAALDH1A1MEN1KMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612054-B2 Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2009-11-03 US disclosed
EP-1651592-B1 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2009-04-29 EP disclosed
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-05-17 US disclosed
EP-1651592-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2006-05-03 EP disclosed
WO-2005014517-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof APP, BACE1, BCHE LMNA 2840/4885STK17B 3288/4885CDK8 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.